Article
Hematology
Alex F. Herrera, Kwang Woo Ahn, Carlos Litovich, Yue Chen, Amer Assal, Qaiser Bashir, Ruthee-Lu Bayer, Melanie Coleman, Zachariah DeFilipp, Nosha Farhadfar, Matthew Greenwood, Theresa Hahn, Mitchell Horwitz, Caron Jacobson, Samantha Jaglowski, Sylvie Lachance, Amelia Langston, Bassam Mattar, Richard T. Maziarz, Joseph McGuirk, Mohammad A. H. Mian, Sunita Nathan, Adrienne Phillips, Kevin Rakszawski, Henrik Sengeloev, Shalini Shenoy, Robert Stuart, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani
Summary: Hematopoietic cell transplantation (HCT), including autologous and allogeneic HCT, may lead to durable remissions in therapy-sensitive patients with Richter syndrome. Complete response was associated with better outcomes in the allo-HCT cohort, while cytogenetic abnormalities and prior novel therapy did not impact outcomes.
Article
Critical Care Medicine
Zhenmei Zhang, Can Wang, Steve G. Peters, William J. Hogan, Shahrukh K. Hashmi, Mark R. Litzow, Mrinal S. Patnaik, Alexander S. Niven, Hemang Yadav
Summary: DAH after HCT has a low incidence rate but high mortality rate, requiring attention. Multiple factors may influence the incidence rate, mortality rate, and risk factors, including time of onset, platelet count, and the need for invasive mechanical ventilation. For treatment outcomes, lower doses of steroids may help improve patient survival.
Article
Multidisciplinary Sciences
Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Daehun Kwag, Byung-Su Kim, Joonyeop Lee, Jong Hyuk Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho
Summary: In this study, we analyzed the clinical characteristics and outcomes of 52 patients with relapsed/refractory diffuse large B cell lymphoma treated with allo-HSCT. Overall survival, event-free survival, and graft-versus-host disease-free, relapse-free survival outcomes were significantly better in patients who achieved remission before allo-HSCT. A shorter interval from diagnosis to allo-HSCT was associated with poorer survival and higher relapse rates. Patients with active disease had lower event-free survival and graft-versus-host disease-free, relapse-free survival.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Hemant S. Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V. Michelis, Taiga Nishihori, Mrinal Patnaik, Muhammad Bilal Abid, Mahmoud Aljurf, Yasuyuki Arai, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Rodrigo Martino, Jean-Yves Cahn, Paul Castillo, Jan Cerny, Saurabh Chhabra, Edward Copelan, Andrew Daly, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Cesar O. Freytes, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Omer Jamy, Jacinth Joseph, Christopher G. Kanakry, Nandita Khera, Maxwell M. Krem, Yachiyo Kuwatsuka, Hillard M. Lazarus, Lazaros J. Lekakis, Hongtao Liu, Dipenkumar Modi, Pashna N. Munshi, Alberto Mussetti, Neil Palmisiano, Sagar S. Patel, David A. Rizzieri, Sachiko Seo, Mithun Vinod Shah, Akshay Sharma, Melhm Sohl, Scott R. Solomon, Matthew Ulrickson, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Trent Wang, Baldeep Wirk, Amer Zeidan, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Daniel J. Weisdorf, Wael Saber, Mohamed A. Kharfan-Dabaja
Summary: This study analyzed the outcomes of allo-HCT in BPDCN patients and found that it provides durable remissions and long-term survival. Younger age and allo-HCT in CR1 were associated with improved survival, while the use of MAC-TBI reduced relapse risk and improved DFS. Further research and innovative strategies are needed to improve the outcomes of BPDCN.
Article
Medicine, General & Internal
Herve Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, M. Trneny, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgues, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Yotam Kolben, Fares Darawshy, Barhoum Barhoum, Avraham Abutbul, Rottem Kuint
Summary: G-CSF, commonly used in healthy adults prior to stem cell donation, can lead to rare but life-threatening pulmonary adverse events such as diffuse alveolar hemorrhage. Healthcare providers should be aware of this potential complication.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Chun-Hui Lee, Tzu-Chien Lin, Ming Yao, Liang-Tsai Hsiao, Bor-Sheng Ko, Chia-Jen Liu, Tsai-Yun Chen
Summary: This study analyzed the long-term follow-up data of patients who underwent allo-HSCT in Taiwan and found that allo-HSCT could be a salvage therapeutic option for relapsed or refractory B-cell lymphoma. Complete remission at the time of allo-HSCT and the presence of GVHD were independent variables for overall survival.
Article
Oncology
Takashi Tanaka, Yoshihiro Inamoto, Ayumu Ito, Mizuki Watanabe, Wataru Takeda, Jun Aoki, Sung-Won Kim, Takahiro Fukuda
Summary: This study retrospectively evaluated the efficacy and safety of lenalidomide in patients with recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. The results showed that lenalidomide may improve survival and administering lenalidomide before mogamulizumab treatment may enhance efficacy.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Alyssa M. Loecher, Kathleen West, Timothy D. Quinn, Aubrey A. Defayette
Summary: DAH is a critical complication that can occur in patients post-HSCT, with treatment options including corticosteroids, aminocaproic acid, and rFVIIa. Further research is needed to explore the efficacy of these treatments for improved outcomes.
Review
Medicine, General & Internal
Mattia Algeri, Pietro Merli, Franco Locatelli, Daria Pagliara
Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) provides a potentially curative treatment for high-risk or relapsed acute leukemia in children by combining intense preparative radio/chemotherapy with the graft-versus-leukemia (GvL) effect. Advances in donor typing, conditioning regimens, GvHD prophylaxis, and MRD-directed interventions have continuously improved transplant outcomes, expanding the potential application of allotransplantation to most patients. Simultaneously, refinements in chemotherapy protocols and targeted therapies may redefine the indications for HSCT in the future.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Michael Y. He, Robert Kridel
Summary: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and the most common subtype of lymphoma. While some patients can be cured, many still experience treatment resistance and poor clinical outcomes. Efforts to improve standard treatments have often been unsuccessful, highlighting the pressing need to understand and manage treatment resistance.
Article
Oncology
Philipp Berning, Norbert Schmitz, Maud Ngoya, Herve Finel, Ariane Boumendil, Fengrong Wang, Xiao-Jun Huang, Olivier Hermine, Laure Philippe, Lucile Couronne, Arnaud Jaccard, Daihong Liu, Depei Wu, Hans Christian Reinhardt, Yves Chalandon, Eva Wagner-Drouet, Mi Kwon, Xi Zhang, Ben Carpenter, Ibrahim Yakoub-Agha, Gerald Wulf, Javier Lopez-Jimenez, Jaime Sanz, Helene Labussiere-Wallet, Avichai Shimoni, Peter Dreger, Anna Sureda, Won Seog Kim, Bertram Glass
Summary: In this study, researchers conducted a retrospective analysis of data from 135 patients with natural killer/T-cell lymphomas (NKTCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that allo-HSCT can achieve long-term survival in NKTCL patients.
Article
Hematology
Sagar S. Patel, Kwang Woo Ahn, Manoj Khanal, Caitrin Bupp, Mariam Allbee-Johnson, Navneet S. Majhail, Betty K. Hamilton, Seth J. Rotz, Hasan Hashem, Amer Beitinjaneh, Hillard M. Lazarus, Maxwell M. Krem, Tim Prestidge, Neel S. Bhatt, Akshay Sharma, Shahinaz M. Gadalla, Hemant S. Murthy, Larisa Broglie, Taiga Nishihori, Cesar O. Freytes, Gerhard C. Hildebrandt, Usama Gergis, Sachiko Seo, Baldeep Wirk, Marcelo C. Pasquini, Bipin N. Savani, Mohamed L. Sorror, Edward A. Stadtmauer, Saurabh Chhabra
Summary: Noninfectious pulmonary toxicity (NPT) is a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), including idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP). This study found that severe pulmonary comorbidity, acute graft-versus-host disease, mismatched unrelated donor and cord blood transplantation, and HCT Comorbidity Index (HCT-CI) score >= 1 were risk factors for developing NPT, while alloHCT performed in 2014 or later, non-total body irradiation-based conditioning, and platelet recovery were associated with a decreased risk of NPT.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Mahmoud R. Gaballa, Pinaki Banerjee, Denai R. Milton, Xianli Jiang, Christina Ganesh, Sajad Khazal, Vandana Nandivada, Sanjida Islam, Mecit Kaplan, May Daher, Rafet Basar, Amin Alousi, Rohtesh Mehta, Gheath Alatrash, Issa Khouri, Betul Oran, David Marin, Uday Popat, Amanda Olson, Priti Tewari, Nitin Jain, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Ken Chen, Richard Champlin, Elizabeth Shpall, Katayoun Rezvani, Partow Kebriaei
Summary: This study examined the feasibility and efficacy of blinatumomab in high-risk acute lymphoblastic leukemia patients after allogeneic hematopoietic cell transplantation. The results showed that blinatumomab treatment was feasible and effective in reducing the risk of relapse, with specific T-cell profiles associated with treatment response.
Review
Oncology
Talal Hilal, Luke J. Mountjoy
Summary: This review summarizes the role of allogeneic hematopoietic stem cell transplant (allo-HSCT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL), with a focus on its role in the era of CAR T-cell therapy. Findings suggest that allo-HSCT is primarily reserved for patients who experience disease progression or relapse after CAR T-cell therapy, and disease status at the time of allo-HSCT is prognostic. Reduced-intensity conditioning (RIC) is likely as effective as myeloablative conditioning (MAC) with less toxicity, and approximately one-third of patients with multiply relapsed disease can be cured with allo-HSCT.
CURRENT ONCOLOGY REPORTS
(2023)